Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...
Analyst Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $994.00. Discover top-rated stocks from highly ranked analysts ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial ...
In the spirit of Christmas, Lilly Roofing is giving away a free new roof in hopes of making a difference in someone’s life.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback